Cargando…
Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase
INTRODUCTION: Fosnetupitant is a novel neurokinin 1 receptor antagonist (NK(1)RA) with favorable antiemetic efficacy in patients receiving emetogenic chemotherapy. This study assessed the efficacy of fosnetupitant in combination with palonosetron and dexamethasone and identified risk factors for che...
Autores principales: | Inui, Naoki, Toi, Yukihiro, Yoneshima, Yasuto, Morise, Masahiro, Hata, Akito, Kubota, Kaoru, Saeki, Toshiaki, Tamura, Tomohide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567891/ https://www.ncbi.nlm.nih.gov/pubmed/37715851 http://dx.doi.org/10.1007/s12325-023-02648-1 |
Ejemplares similares
-
Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE
por: Hata, Akito, et al.
Publicado: (2022) -
Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE)
por: Hata, Akito, et al.
Publicado: (2022) -
Multicenter, placebo‐controlled, double‐blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
por: Sugawara, Shunichi, et al.
Publicado: (2019) -
A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE‐BC
por: Matsuura, Kazuo, et al.
Publicado: (2022) -
Fosnetupitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Short Review and Clinical Perspective
por: Abe, Masakazu, et al.
Publicado: (2023)